Chrysalis Pharma is an emerging pharmaceutical company developing drugs against immunological inflammation.
Chrysalis-Pharma invents new immunological drugs against inflammation.
For this research, Chrysalis-Pharma obtained a first prize OSEO at its inception in 2009.
The immunological inflammation is an inflammation caused by immune inflammatory cells, basophil, eosinophil and mast cells. While many drugs act on the substances secreted by these cells, drugs that develops Chrysalis-Pharma act directly on the inflammatory cells by blocking their multiplication.
H4 agonists are a new patented medicines concept
This new class of drugs used to treat many immunological inflammatory diseases, including Idiopathic Pulmonary Fibrosis.
Chrysalis-Pharma has patented several molecules in this new therapeutic class for the treatment of cystic fibrosis and idiopathic pulmonary fibrosis.
The first results were obtained in animals and give superior results to molecules already marketed in these indications.